Physician profile
Stuart Alan Shapiro
NPI 1346241429
$1,184.14
in general payments reported to CMS, 2019-2025
15 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $305 · 2021: $79.82 · 2022: $115 · 2023: $90.02 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $423.53 | 2019-2023 | |
| Novo Nordisk INC | $165.94 | 2019-2023 | Ozempic, Rybelsus |
| Inspire Medical Systems, INC. | $122.54 | 2025 | Inspire |
| Lilly USA, LLC | $110.66 | 2020-2023 | Mounjaro |
| Pfizer INC. | $64.78 | 2019-2022 | |
| Astellas Pharma US INC | $43.43 | 2019 | |
| Sanofi Pasteur INC. | $43.00 | 2019-2020 | |
| Amarin Pharma, INC. | $38.56 | 2019-2021 | |
| Allergan, INC. | $38.33 | 2020 | |
| Merck Sharp & Dohme LLC | $31.52 | 2019-2022 | |
| Glaxosmithkline, LLC. | $31.42 | 2020-2021 | |
| Abbott Laboratories | $24.61 | 2022 | |
| Bausch Health US, LLC | $20.58 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.24 | 2019 | |
| Circassia INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.